Results from Phase 3 Study - Once Weekly Exenatide LAR
Friday, January 10th, 2003Good News.
*Once Weekly Exenatide LAR Well Tolerated and Improved Glucose Control;
Preliminary Results From Phase 2 Study Announced*
SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 22,
2005–Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and
Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced
results from the ongoing Phase 2 multi-dose study of a long-acting
release (LAR) formulation of BYETTA(TM) (exenatide) injection in
patients with type 2 diabetes.
The study was designed to assess the safety, tolerability and
pharmacokinetics of exenatide LAR given once a week. After 15 weeks,
both doses of exenatide LAR were well tolerated and expected therapeutic